推薦產品
化驗
≥98% (HPLC)
形狀
powder
顏色
white to beige
溶解度
H2O: 2 mg/mL, clear
儲存溫度
−20°C
SMILES 字串
S([C@@H]2O[C@@H]([C@@H]([C@@H]([C@H]2O)O)O)CO)C1O[C@@H]([C@@H]([C@@H]([C@H]1O)O)O)CO
InChI
1S/C12H22O10S/c13-1-3-5(15)7(17)9(19)11(21-3)23-12-10(20)8(18)6(16)4(2-14)22-12/h3-20H,1-2H2/t3-,4-,5+,6+,7+,8+,9-,10-,11+,12?/m1/s1
InChI 密鑰
SYKYBMOFPMXDRQ-VVLLKYQZSA-N
尋找類似的產品? 前往 產品比較指南
生化/生理作用
Thiodigalactoside (TDG)is a potent inhibitor of galectin-1 (GAL1) that suppress tumor growth by inhibiting multiple cancer enhancing activities of galectin-1, including immune cell dysregulation, angiogenesis and protection against oxidative stress. Thiodigalactoside reverses galectin-1-induced cisplatin resistance in HCC cells. Thiodigalactoside significantly reduces body weight gain in diet-induced obese rats.
儲存類別代碼
11 - Combustible Solids
水污染物質分類(WGK)
WGK 3
閃點(°F)
Not applicable
閃點(°C)
Not applicable
Oral diseases, 22(5), 445-453 (2016-03-24)
Thiodigalactoside (TDG), a synthetic inhibitor of β-galactoside-binding protein (β-GBP) suppresses tumour growth by inhibiting multiple cancer enhancing activities of β-GBP. Hence, we attempted to understand whether disruption of β-GBP functions and indirect inhibition of Treg cells by TDG affect the
PloS one, 11(2), e0148408-e0148408 (2016-02-10)
Hepatocellular carcinoma (HCC) is one of the most common cancers in Taiwan. Although chemotherapy is the primary treatment for HCC patients, drug resistance often leads to clinical failure. Galectin-1 is a beta-galactoside binding lectin which is up-regulated in HCC patients
Cell reports, 37(4), 109892-109892 (2021-10-22)
The main viral protease (3CLpro) is indispensable for SARS-CoV-2 replication. We delineate the human protein substrate landscape of 3CLpro by TAILS substrate-targeted N-terminomics. We identify more than 100 substrates in human lung and kidney cells supported by analyses of SARS-CoV-2-infected
International journal of molecular sciences, 16(7), 14441-14463 (2015-06-30)
Previously, galectin-1 (GAL1) was found to be up-regulated in obesity-prone subjects, suggesting that use of a GAL1 inhibitor could be a novel therapeutic approach for treatment of obesity. We evaluated thiodigalactoside (TDG) as a potent inhibitor of GAL1 and identified
我們的科學家團隊在所有研究領域都有豐富的經驗,包括生命科學、材料科學、化學合成、色譜、分析等.
聯絡技術服務